AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

Search

GlaxoSmithKline PLC

Отворен

СекторЗдравеопазване

1,456 2.64

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1415.5

Максимум

1462.5

Ключови измерители

By Trading Economics

Приходи

559M

501M

Продажби

105M

8.1B

P/E

Средно за сектора

23.581

63.778

EPS

0.232

Дивидентна доходност

4.3

Марж на печалбата

6.172

Служители

68,629

EBITDA

-52M

1.1B

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+8.46% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

4.30%

2.39%

Следващи печалби

30.04.2025 г.

Следваща дата на дивидент

10.04.2025 г.

Следваща дата на екс-дивидент

15.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-586M

59B

Предишно отваряне

1453.36

Предишно затваряне

1456

Настроения в новините

By Acuity

38%

62%

139 / 386 Класиране в Healthcare

GlaxoSmithKline PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.02.2025 г., 11:32 ч. UTC

Печалби

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook -- 2nd Update

5.02.2025 г., 08:56 ч. UTC

Печалби

Correction to GSK Article

5.02.2025 г., 08:24 ч. UTC

Печалби

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views -- Update

5.02.2025 г., 07:43 ч. UTC

Печалби

GSK Expects Further Profit Growth After Beating Market Views

13.01.2025 г., 07:14 ч. UTC

Придобивния, сливания и поглъщания

GSK to Buy U.S. Rare Tumor Specialist IDRx for Up to $1.15 Billion

2.04.2025 г., 09:27 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26.03.2025 г., 22:29 ч. UTC

Топ новини

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26.03.2025 г., 19:19 ч. UTC

Топ новини

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26.03.2025 г., 17:39 ч. UTC

Топ новини

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

19.03.2025 г., 14:50 ч. UTC

Топ новини

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

17.03.2025 г., 09:00 ч. UTC

Топ новини

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

24.02.2025 г., 07:05 ч. UTC

Придобивния, сливания и поглъщания

GSK Completes Acquisition of IDRx

14.02.2025 г., 11:38 ч. UTC

Топ новини
Печалби

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

14.02.2025 г., 11:30 ч. UTC

Топ новини
Печалби

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

5.02.2025 г., 15:33 ч. UTC

Пазарно говорене
Печалби

GSK's Pipeline Has to Prove It Can Counter Concerns Over Vaccine Business -- Market Talk

5.02.2025 г., 08:38 ч. UTC

Пазарно говорене
Печалби

GSK Needs to Show It Can Navigate Vaccines Challenge -- Market Talk

5.02.2025 г., 07:05 ч. UTC

Печалби

GSK PLC Had Seen 2031 Sales Outlook at More Than GBP38B

5.02.2025 г., 07:04 ч. UTC

Печалби

GSK PLC Sees 2031 Sales Outlook at More Than GBP40B

5.02.2025 г., 07:03 ч. UTC

Печалби

GSK PLC Sees 2025 Adjusted EPS Growth of 6%-8%

5.02.2025 г., 07:03 ч. UTC

Печалби

GSK PLC Raises Mid-Term View

5.02.2025 г., 07:03 ч. UTC

Печалби

GSK PLC Sees 2025 Adjusted Operating Growth of 6% - 8%

5.02.2025 г., 07:02 ч. UTC

Печалби

GSK PLC Sees 2025 Turnover Growth of 3% to 5%

5.02.2025 г., 07:02 ч. UTC

Печалби

GSK PLC Issues GBP2B Buyback

5.02.2025 г., 07:01 ч. UTC

Печалби

GSK PLC Declares 4Q Dividend of 16p

5.02.2025 г., 07:00 ч. UTC

Печалби

GSK PLC 4Q Core EPS Consensus Was 20.6p

5.02.2025 г., 07:00 ч. UTC

Печалби

GSK PLC 4Q Sales Consensus Was GBP7.83B

5.02.2025 г., 07:00 ч. UTC

Печалби

GSK PLC 4Q Pretax Pft GBP563M

5.02.2025 г., 07:00 ч. UTC

Печалби

GSK PLC 4Q EPS 10.0p

5.02.2025 г., 07:00 ч. UTC

Печалби

GSK PLC 4Q Adj EPS 23.2p

5.02.2025 г., 07:00 ч. UTC

Печалби

GSK PLC 4Q Oper Pft GBP696M

Сравнение с други в отрасъла

Ценова промяна

GlaxoSmithKline PLC Прогноза

Ценова цел

By TipRanks

8.46% нагоре

12-месечна прогноза

Среден 1,593.33 GBX  8.46%

Висок 2,290 GBX

Нисък 1,450 GBX

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за GlaxoSmithKline PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

12 ratings

2

Купи

8

Задържане

2

Продай

Настроение

By Acuity

139 / 386 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.